Curcumin

Scientists created a multifunctional nanotherapy that aims to overcome the limitations of conventional periodontal treatments CHINA, July 16, 2026 / EINPresswire.com / -- Millions of people worldwide live with periodontitis, a chronic gum disease that can progressively destroy the tissues and bone supporting the teeth despite conventional treatment. Seeking a more comprehensive solution, researchers developed a novel DNA-based nanoplatform designed to deliver multiple therapeutic agents in a single package. By targeting the complex biological processes that drive the disease, this innovative approach represents a promising step toward next-generation therapies for chronic oral inflammation. Periodontitis is one of the most common chronic inflammatory diseases worldwide and a leading cause of tooth loss in adults. Triggered by bacterial plaque that accumulates beneath the gums, the disease sets off an immune response that gradually destroys the tissues and bone supporting the teeth. While treatments such as antibiotics and deep cleaning can reduce bacterial burden, they often do not fully halt disease progression or repair existing damage. These limitations have driven growing interest in therapies that can address the multiple biological processes underlying the disease. With this goal in mind, a research team from Sichuan University—led by Dr. Geru Zhang, Professor Yunfeng Lin, and Professor Xiaoxiao Cai—developed a DNA-based nanotherapy that combines several therapeutic functions within a single platform. “We aimed to create a multifunctional DNA nanoplatform capable of delivering both curcumin and the antimicrobial peptide defensin directly to periodontal tissues, with the goal of overcoming the limitations of existing therapies,” shares Dr. Zhang. By packaging both compounds into a DNA nanostructure, the team sought to create a more comprehensive approach to treating periodontitis. The study was published in Volume 18 of the International Journal of Oral Science on April 29, 2026. To evaluate the platform, the researchers engineered a DNA nanocomplex known as Cur-de-tFNA by loading curcumin and defensin onto tetrahedral framework nucleic acids (tFNAs). They characterized its physical properties, stability, and drug-loading efficiency before testing its performance in human periodontal ligament stem cells (PDLSCs). The complex’s antibacterial activity was tested against major periodontal pathogens, while its anti-inflammatory, antioxidant, and bone-regenerative effects were evaluated in lipopolysaccharide-stimulated PDLSCs through molecular and cellular assays. Therapeutic efficacy and safety were investigated in a rat model of periodontitis using imaging, histological analyses, and molecular assays. The results showed that the Cur-de-tFNA nanocomplex effectively tackled several hallmarks of periodontitis. It demonstrated potent antibacterial activity against key disease-causing microbes, suppressed oxidative stress and inflammatory signaling by inhibiting the TLR4/NF-κB pathway, and promoted the expression of proteins involved in bone formation. In rats with periodontitis, treatment reduced alveolar bone loss, limited inflammatory damage, decreased osteoclast activity, and enhanced collagen deposition and new bone formation. Across multiple experiments, the combined nanotherapy consistently outperformed its individual components. A major strength of the platform lies in its integrated design. “The DNA carrier enhanced the stability and cellular uptake of curcumin while protecting defensin from degradation, allowing both therapeutic agents to function more effectively,” shares Prof. Lin. Prof. Cai adds, “As a result, the nanoplatform delivered stronger antimicrobial activity, better control of inflammation, and improved preservation of periodontal tissues in preclinical models.” Moreover, because it is biodegradable and composed entirely of natural nucleic acids, the carrier exhibited excellent biocompatibility and a favorable safety profile, further supporting its potential for future clinical applications. Although the findings are currently limited to laboratory and animal studies, they point toward a promising new direction for periodontitis therapy. Following further validation in larger animal models and human clinical trials, multifunctional DNA nanoplatforms such as Cur-de-tFNA could offer treatments that not only suppress disease progression but also help regenerate damaged periodontal tissues. The same strategy may eventually prove valuable for other disorders involving chronic inflammation, bacterial infection, and bone loss. Overall, this study highlights the promise of a multifunctional DNA nanomedicine capable of simultaneously targeting bacterial infection, chronic inflammation, and bone destruction—the three hallmarks of periodontitis. By enhancing the delivery and effectiveness of curcumin and defensin, the Cur-de-tFNA platform offers a compelling proof of concept for more holistic management of periodontitis and potentially other inflammatory diseases. Reference Title of original paper: DNA framework-based nanomedicine platform: a triple-function strategy for treating periodontitis via antibacterial, anti-inflammatory, and osteogenesis-promoting activities Journal: International Journal of Oral Science DOI: https://doi-org.libproxy1.nus.edu.sg/10.1038/s41368-026-00439-2 About Sichuan University Sichuan University is a research university located in Chengdu, China, and widely recognized as one of the country’s leading higher education institutions. It was formed through the merger of several historic universities, including the former West China University of Medical Sciences, giving it a strong foundation in medical and health sciences. The university offers a broad range of disciplines across medicine, engineering, natural sciences, humanities, and social sciences. Its West China medical campuses, particularly the West China Hospital of Stomatology, are internationally recognized for dental and biomedical research. Sichuan University is part of China’s elite “Double First-Class” initiative. Website: https://en.scu.edu.cn/ About Dr. Geru Zhang from Sichuan University Dr. Geru Zhang is a researcher affiliated with Sichuan University, with work associated with the West China Hospital of Stomatology and the State Key Laboratory of Oral Diseases. He has authored or co-authored approximately 18 peer-reviewed publications over several years of research experience, focusing on DNA nanotechnology, biomaterials, regenerative medicine, drug delivery systems, and oral disease therapeutics. His research has contributed to the development of tetrahedral framework nucleic acid (tFNA)-based platforms for applications such as periodontitis treatment, wound healing, and nasal-to-brain drug delivery. Funding information This study was supported by the National Natural Science Foundation of China (82370929), National Natural Science Fund for Young Scientists Fund Program C (82501707, 82501232), the General Program of the China Postdoctoral Science Foundation, the Postdoctoral Fellowship Program of CPSF under Grant (GZC20251341). the Sichuan Science and Technology Program (2022NSFSC0002), the Sichuan Province Youth Science and Technology Innovation Team (2022JDTD0021), the Health Commission of Sichuan Province Medical Science and Technology Program, the Sichuan Province Innovative Talent Funding Project for Postdoctoral Fellows (Grant No. BX202410), the Sichuan Provincial Natural Science Youth Foundation. (Grant No.2025ZNSFSC1649), Sichuan University Interdisciplinary Innovation Fund and the Research and Development Program of West China Hospital of Stomatology, Sichuan University (RD03202302, RCDWJS2024-1). Yini Bao International Journal of Oral Science +862885546461 ext. email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

SUMMIT, N.J., June 24, 2026 /PRNewswire/ -- Vascarta Inc., a clinical-stage biopharmaceutical company advancing innovative treatments for pain and inflammation, announced today the successful completion of the sublingual arm of its Phase I clinical trial evaluating VAS-101 (Vasceptor®; topical curcumin gel) for the treatment of sickle cell disease (SCD). The study was conducted by the Foundation for Sickle Cell Disease Research (FSCDR) in Hollywood, Florida, under the supervision of the principal investigator, Dr. Gershwin Blyden. The findings were published today in the Journal of Sickle Cell Disease: Low-Dose Sublingual Curcumin Improves Red Blood Cell Sickling Kinetics in Sickle Cell Disease: Interim Results from a Pilot Study | Journal of Sickle Cell Disease | Oxford Academic Five (5) patients with sickle cell disease were treated sublingually with a minimal dosing (0.1 mL) of VAS-101 twice per week for a total of 8 treatments. Their blood was drawn and analyzed weekly. The duration of treatment was 29 days. All participants demonstrated favorable safety and tolerability. Directional improvements were observed across several patient-reported outcomes. Mean pain scores decreased from 7.0 at baseline to 6.6 by Day 15, with several participants demonstrating clinically meaningful reductions from baseline. Measures of fatigue and energy also improved, with out-of-energy scores decreasing from 3.6 at baseline to 2.2 by Day 22 and fatigue limits improving from 2.8 to 2.0. Psychosocial ePRO measures showed stability or improvement across most participants, including reductions in worry, loneliness, and depressive symptoms. Assessment of red blood cell (RBC) functional biomarkers demonstrated improvements as measured by the DSA. From baseline to Day 29, the Area Under the Curve (AUC10) decreased from 419±140 to 394±118 %*min. Morphological Point of Sickling at 50% (mPoS@50%) increased from 4.9±1.0 to 5.5±1.2 minutes, indicating a delay in sickling. Additionally, the rate of sickling decreased from 47±23 to 38±17 %/min. Collectively, these changes reflect improved sickling kinetics over the treatment period. FA-WB-VCAM and FA-WB-Psel adhesion indices (fAI) were below previously established critical thresholds (FA-WB-VCAM:400 cells/mm2, FA-WB-Psel:50 cells/mm2) predictive of future self-reported vaso-occlusive crises, VOCs in four (4) subjects at baseline and, as expected, no improvements in adhesion were seen at Day 29. Only a single participant exhibited a baseline FA-WB-VCAM fAI exceeding the clinical threshold (>502 cells/mm²). Red blood cell mechanical fragility indices (MFI) were within normal range at baseline and remained stable over the course of the study. Baseline concentrations of standard inflammatory markers were and remained below the lower limit of detection for the initial three participants; consequently, further analytical testing was suspended. VAS-101 demonstrated safety and tolerability in the sublingual cohort. Improvements in integrated ePRO and RBC functional biomarkers were noted suggesting potential mechanistic and patient-centered benefits of VAS-101 in individuals with SCD. The resulting biomarkers shift at low dose supports advancement towards dose optimization. Future studies evaluating higher dose and frequency may yield greater improvements in pain, ePRO measures, and laboratory biomarkers. Pre-selecting a cohort that exhibits a higher adhesive burden, indicative of more inflammation may show further improvements in RBC health normalization. Dr. Lanetta Bronté, President of FSCDR, commented, "I'm proud that we are taking part in Vascarta's pilot study, which explores a new transdermal approach to pain management for individuals living with Sickle Cell Disease (SCD). Pain remains one of the most challenging and life-disrupting aspects of this disease, and new approaches are urgently needed. While early in development, this research represents an important step toward finding new options that could one day help ease that burden. At FSCDR, we are committed to advancing care and bringing hope to the SCD community through innovation and collaboration." About VAS-101 VAS-101 (developed by Vascarta Inc., Summit, NJ) is a topical curcumin formulation that employs a patented transdermal delivery technology designed to increase bioavailability. Note: Curcumin possesses many beneficial attributes such as safety, anti-sickling, anti-inflammatory, and antioxidant properties, but its translational potential has been constrained due to limited bioavailability from oral administration. It is being clinically evaluated in several chronic inflammatory indications. Unmet Need In Sickle Cell Disease Sickle cell disease is the most common inherited genetic disorder that effects primarily African American and non – Hispanic Black individuals in the United States. SCD associated complications include anemia, acute and chronic pain, infections, pneumonia and acute chest syndrome, stroke, and kidney, liver, and heart disease. Current estimates indicate there are >165,000 cases of SCD in the USA & 45,000 in European Union countries. The estimated life expectancy of those with sickle cell disease in the USA is more than 20 years shorter than the average expected lifespan. SCD is caused by a single point mutation in the globin gene leading to sickling of red blood cells. It is characterized by severe pain, inflammation, oxidative stress, and organ damage, which contribute to the poor quality of life and reduced survival. Recently approved SCD therapies do not mitigate pain and patients are often on multiple drugs which often have undesirable side effects. The unmet medical need for most SCD sufferers is significant. Better therapies that optimize compliance are appropriate for patients of all ages, minimize the need for blood transfusions, and reduce the need for chronic administration of potentially harmful pain medications are needed. Leadership Perspectives Dr. Richard Prince, Vascarta Chairman, CEO & President commented, "We are excited at the prospect of bringing relief to SCD sufferers who have limited therapeutic options. VAS-101 has the potential to become the new standard of care in the management of SCD. Independent of the FSCDR clinical findings presented herein, we have made VAS-101 (Vasceptor®) available to patients – given the well-recognized safety profile of curcumin - through a single 503A compounding pharmacy provided these patients obtain a prescription from a US-licensed physician. These results, in aggregate, are promising. We are working towards filing an Investigational New Drug Application with FDA later this year in furtherance of our VAS-101 sickle cell clinical development program." Dr. Joel Friedman, Emeritus Professor, Department of Microbiology & Immunology, Albert Einstein College of Medicine, and Vascarta Scientific Founder & Chief Science Officer is the inventor of VAS-101 which is exclusively licensed to Vascarta from the Albert Einstein College of Medicine (Bronx, New York, USA). He underscores the powerful potential of VAS-101: "The preclinical and clinical results to date demonstrate pain reduction and therapeutic efficacy resulting from our novel approach of targeting red blood cell instability, neuro-inflammation and vascular inflammation." Dr. Friedman noted an anecdotal but exceptional result from "a sickle cell patient who had been suffering intense severe pain upon onset of menstruation. Sublingual administration of Vasceptor®, obtained through a Ramsey, New Jersey-based 503A compounding pharmacy, caused her pain to subside and remain pain-free until her next period, whereupon the pattern repeats. It is now 12 consecutive months and Vasceptor® has maintained the same analgesic effect for this patient. These clinical advances support the development of Vasceptor® as a potential therapy to prevent and treat many of the clinical sequelae of SCD." About Vascarta Vascarta is a clinical stage pharmaceutical company exploring efficient transdermal delivery of pharmaceuticals to address inflammation and pain with an initial focus on sickle cell disease and osteoarthritis. More information can be found at or by email to: Dr. Richard Prince, Chairman, CEO & President – [email protected] Media inquiries: David Hymson at [email protected] SOURCE Vascarta Inc. 21% more press release views with Request a Demo